Skip to main content

Lipella Pharmaceuticals Inc.

LIPO
Industry
Pharmaceutical Preparations
SEC CIK
0001347242

No open-market purchases or sales by Lipella Pharmaceuticals Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Lipella Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Lipella Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Lipella Pharmaceuticals Inc.
NameTitleLast reported holdingLast filingFilings, past year
Kaufman Jonathan HSee remarks below.898,849Apr 7, 20250
Kim ByongDirector–Mar 19, 20240
Pruchnic RyanDirector–Mar 19, 20240
Johnston DouglasChief Financial Officer–Mar 19, 20240
Chancellor Michael BChief Medical Officer877,637Mar 19, 20240
Yoshimura NaokiDirector–Mar 19, 20240
Cohen Daniel RDirector–Mar 19, 20240
Birder LoriDirector–Mar 19, 20240
Battleman David S.Director–Jun 21, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 15, 2024 (view filing)May 141 dayKaufman Jonathan HSee remarks below.PPurchase+10.0K$0.76+$7.60K+1.1%898.8K after
Mar 19, 2024 (view filing)Mar 18-191 dayKaufman Jonathan HSee remarks below.PPurchase+55.0K$0.8264+$45.5K+6.6%888.8K after2 lots